Skip to main
SYRE

SYRE Stock Forecast & Price Target

SYRE Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spyre Therapeutics Inc. is positioned favorably within the biotechnology sector due to its innovative approach in targeting inflammatory bowel disease (IBD) through advanced antibody engineering and combination therapies. The company's product, SPY003, not only promises to decrease the injection burden with maintenance doses as infrequent as every six months but also demonstrates substantial therapeutic synergy when used in combination regimens, enhancing its potential market value. Additionally, the strong target engagement metrics associated with tulisokibart, which offers more than fourfold greater engagement than competing therapies, suggest a competitive edge in efficacy and patient outcomes within the IBD treatment landscape.

Bears say

Spyre Therapeutics faces a negative outlook due to significant challenges associated with prior bispecific antibodies, which exhibited extremely high immunogenicity rates ranging from 72% to 100% in healthy volunteers, raising concerns about product safety and efficacy. Additionally, the emergence of JNJ-4804, a competing co-formulation demonstrated to have a substantially lower immunogenicity rate of merely 6%, may hinder Spyre's ability to position its products competitively in the market. These factors, combined with the inherent complexity of optimizing treatment solutions in a landscape dominated by established products, point to potential hurdles in achieving successful market penetration and financial viability.

SYRE has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spyre Therapeutics Inc (SYRE) Forecast

Analysts have given SYRE a Strong Buy based on their latest research and market trends.

According to 6 analysts, SYRE has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spyre Therapeutics Inc (SYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.